2024
Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation
May C, Noble P, Herzog E, Meffre E, Hansen J. Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation. Biochemical And Biophysical Research Communications 2024, 720: 150123. PMID: 38759301, DOI: 10.1016/j.bbrc.2024.150123.Peer-Reviewed Original ResearchDiffuse cutaneous systemic sclerosisCutaneous systemic sclerosisAnti-topoisomerase 1Systemic lupus erythematosusDiscovery of autoantibodiesMechanisms of autoimmunityInhibit DNA repairScleroderma autoantibodiesScleroderma subtypeSystemic sclerosisLupus erythematosusAutoantibodiesCancer therapyPathophysiologyReagent resourcesCellular dysfunctionAntibodiesCell nucleiDNA repair
2015
Optimizing a Lupus Autoantibody for Targeted Cancer Therapy
Noble PW, Chan G, Young MR, Weisbart RH, Hansen JE. Optimizing a Lupus Autoantibody for Targeted Cancer Therapy. Cancer Research 2015, 75: 2285-2291. PMID: 25832653, DOI: 10.1158/0008-5472.can-14-2278.Peer-Reviewed Original Research
2014
A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells
Noble PW, Young MR, Bernatsky S, Weisbart RH, Hansen JE. A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells. Scientific Reports 2014, 4: 5958. PMID: 25091037, PMCID: PMC5380011, DOI: 10.1038/srep05958.Peer-Reviewed Original ResearchConceptsLupus autoantibodiesTherapeutic agentsCancer cellsSystemic lupus erythematosusBRCA2-deficient cellsLupus erythematosusBRCA2-deficient cancer cellsDLD1 colon cancer cellsColon cancer cellsSuch antibodiesLower riskAutoantibodiesSpecific cancersAntibodiesMalignancyDifferential effectsToxic effectsPotential utilityCellsAgentsFurther supportDNA-damaging agentsErythematosusTherapyCancer
2012
A Cell-Penetrating Bispecific Antibody for Therapeutic Regulation of Intracellular Targets
Weisbart RH, Gera JF, Chan G, Hansen JE, Li E, Cloninger C, Levine AJ, Nishimura RN. A Cell-Penetrating Bispecific Antibody for Therapeutic Regulation of Intracellular Targets. Molecular Cancer Therapeutics 2012, 11: 2169-2173. PMID: 22863609, DOI: 10.1158/1535-7163.mct-12-0476-t.Peer-Reviewed Original ResearchConceptsBispecific antibodiesBispecific single-chain Fv fragmentsMonoclonal antibody 3G5Cancer therapyDelivery of antibodiesIntracellular targetsMolecular therapyTherapeutic useTherapeutic regulationMonoclonal antibodiesTherapyAntibodiesMAb 3E10Single-chain Fv fragmentInhibits growthP53 levelsImportant targetMDM2Limited accessFv fragmentTargetTumors
2004
Antibody-mediated transduction of p53 selectively kills cancer cells.
Weisbart RH, Hansen JE, Chan G, Wakelin R, Chang SS, Heinze E, Miller CW, Koeffler PH, Yang F, Cole GM, Min YS, Nishimura RN. Antibody-mediated transduction of p53 selectively kills cancer cells. International Journal Of Oncology 2004, 25: 1867-73. PMID: 15547728, DOI: 10.3892/ijo.25.6.1867.Peer-Reviewed Original ResearchConceptsCancer cellsWild-type p53Expression of MDM2Cancer cell linesTransduction of p53Potential efficacyCertain cancersNon-specific toxicityFunctional defectsHuman cancersP53Cell linesCancerResult of mutationsGene therapyPrimary cellsViral vectorsCellsVivoNuclear exclusionTherapyFusion proteinFv fragmentProtein transductionAntibodies